Trial Profile

A Phase 1/1b Dose-Escalation Trial Evaluating CPI-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects With Relapsed/Refractory T-Cell Lymphoma

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 03 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Soquelitinib (Primary)
Indications Anaplastic large cell lymphoma; Cutaneous T-cell lymphoma; Peripheral T-cell lymphoma; T-cell leukaemia; T-cell lymphoma
Focus Adverse reactions; First in man
Sponsors Corvus Pharmaceuticals

Most Recent Events

27 Aug 2026 According to a Corvus Pharmaceuticals media release, the company announced the publication of peer-reviewed final data from its Phase 1/1b trial of soquelitinib in patients with T cell lymphoma in the journal of the American Society of Hematology.
27 Aug 2026 Results published in a Corvus Pharmaceuticals Media Release.
08 Dec 2025 Results presented in the Corvus Pharmaceuticals Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com